The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12 hours of acute ischemic stroke (AIS) in China. Patients were randomly assigned to receive a 10-day infusion of dl-3-n-butylphthalide (NBP) or cerebrolysin, or placebo. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) were used to evaluate the efficacy in the patients with AIS at 11-day and 21-day after therapy. Adverse events were also analyzed among the three groups.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
84
Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.
Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.
100 ml saline intravenous infusion once daily for 10 days.
Shanghai Sixth People's Hospital
Shanghai, China
National Institutes of Health Stroke Scale Score
Scores range from 0 to 42, with higher scores indicating increasing severity
Time frame: At 11-day and 21-day after therapy
Barthel Index Score
Range from 0, indicating complete dependence on help with activities of daily living, to 100, indicating independence
Time frame: At 11-day and 21-day after therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.